Jinyun Ma

Jinyun Ma

Auto-generated profile, based on publicly available information

Jinyun Ma

Institute of Clinical Immunology, Yue‐Yang Hospital of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XLXiaojun Liu
Xiaojun Liu
JMJinyun Ma
Jinyun Ma
GDGuiqing Ding
Guiqing Ding
QGQianyi Gong
Qianyi Gong
YWYuanhua Wang
Yuanhua Wang
XCXiaodong Cheng
Xiaodong Cheng
Activated microglia is considered to be major mediators of the neuroinflammatory environment in demyelinating diseases of the central nervous system (CNS). Activated microglia are mainly polarized into M1 type, which plays a role in promoting inflammation and demyelinating. However, the proportion of microglia polarized into M2 type is relatively low, which cannot fully play the role of anti‐inflammatory and resistance to demyelinating. Our previous study found that Astragalus polysaccharides (APS) has an immunomodulatory effect and can inhibit neuroinflammation and demyelination in experimental autoimmune encephalomyelitis (EAE), which is a classic animal model of CNS demyelinating disease. In this study, we found that APS was effective in treating EAE mice. It restored microglia balance by inhibiting the polarization of microglia to M1‐like phenotype and promoting the polarization of microglia to M2‐like phenotype in vivo and in vitro. miR‐155 is a key factor in regulating microglia polarization. We found that APS could inhibit the expression level of miR‐155 in vivo and in vitro. Furthermore, we performed transfection overexpression and blocking experiments. The results showed that miR‐155 mediated the polarization of microglia M1/M2 phenotype, while the selective inhibitor of miR‐155 attenuated the inhibition of APS on microglia M1 phenotype and eliminated the promotion of APS on microglia M2 phenotype. Microglia can secrete IL‐1α, TNF‐α, and C1q after polarizing into M1 type and induce the activation of A1 neurotoxic astrocytes, further aggravating neuroinflammation and demyelination. APS reduced the secretion of IL‐1α, TNF‐α, and C1q by activated microglia, thus inhibited the formation of A1 neurotoxic astrocytes. In summary, our study suggests that APS regulates the polarization of microglia from M1 to M2 phenotype by inhibiting the miR‐155, reduces the secretion of inflammatory factors, and inhibits the activation of neurotoxic astrocytes, thus effectively treating EAE.

13 December 2024 in Brain Research Bulletin
Verified
Journal Article
Open access
JMJinyun Ma
Jinyun Ma
XLXiaojun Liu
Xiaojun Liu
YZYan Zhao
Yan Zhao
QLQijin Lu
Qijin Lu
GDGuiqing Ding
Guiqing Ding
XCXiaodong Cheng
Xiaodong Cheng
The Th17/Treg imbalance is an important cause of immune cell infiltration into the central nervous system (CNS) in multiple sclerosis (MS). The gut microbiota affects the Th17/Treg balance in the gut and in distal areas, such as the CNS, which further contributes to the onset and progression of MS. Our previous studies have shown that Astragalus polysaccharide (APS) has a role in alleviating the clinical symptoms and demyelination of experimental autoimmune encephalomyelitis (EAE) mice, a classic MS model. However, the mechanism of action is not fully understood. In this study, we found that APS suppressed inflammation and regulated the Th17/Treg balance in the CNS and peripheral blood of EAE mice. It was further shown that APS inhibited gut inflammation and reduced Th17 function. The experiment with an antibiotic cocktail interfering with the gut microbiota proved that APS alleviated EAE by regulating the gut microbiota. Through 16S rRNA sequencing, we showed that APS regulated gut microbiota diversity and composition in EAE mice. Then, we found that APS regulated metabolite composition in feces and plasma, thus altering gut and blood metabolic functions. Metabolites related to this pathway, including sphingosine 1 phosphate (S1P), prostaglandin E2 (PGE2), ADP, and ATP, were downregulated by APS. The levels of bile acid metabolites such as taurochenodeoxycholate-7-sulfate and N-palmitoyl aspartic acid were upregulated by APS. In summary, our study demonstrated that APS exerts a suppressive effect on EAE by regulating gut microbiota composition, affecting metabolite composition, and improving the Th17/Treg balance in the peripheral blood and CNS.

14 April 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XQXi Qiao
Xi Qiao
GDGuiqing Ding
Guiqing Ding
QLQijin Lu
Qijin Lu
YCYuxin Chen
Yuxin Chen
XWXiaohan Wang
Xiaohan Wang
XCXiaodong Cheng
Xiaodong Cheng
Astragalus polysaccharides (APS) exhibits potent immunomodulatory properties, yet its interplay with intratumoral microbiota in driving antitumor immunity remains elusive. Herein, we demonstrate that APS suppresses melanoma growth and prolongs survival by inducing immunogenic cell death (ICD) via the cGAS‐STING pathway. Inhibition of cGAS‐STING abrogated APS efficacy. Notably, depletion of intratumoral microbiota using antibiotics blunted APS‐mediated cGAS‐STING activation and immune responses, confirming a microbiota‐dependent mechanism. 5R 16S rRNA sequencing identified Pseudomonas enrichment as a distinct signature of APS treatment. Crucially, administration of Pseudomonas sterile supernatant was sufficient to activate cGAS‐STING signaling, induce ICD, and inhibit tumor growth in microbiota‐depleted mice. We propose that APS acts as an upstream modulator that enriches Pseudomonas, creating a microenvironment where bacterial secretions trigger the cGAS‐STING pathway to induce ICD. These findings provide a novel theoretical basis for microbiota‐targeted immunotherapies.